LIMS Integration — The Quiet Wedge
LIMS (Laboratory Information Management Systems) is where the lab's institutional memory lives. STARLIMS, LabWare, LabVantage, Benchling, SampleManager — every serious lab has one, and most are 10–20 years old, painful to extend, and unloved. LabOS being LIMS-native is the quiet wedge that converts a "platform sale" into an "infrastructure upgrade." Buyers approve infrastructure upgrades. Buyers stall on platform sales.
Why LIMS is the wedge
- Already budgeted: labs spend $50K–$500K/year per site on LIMS. We replace or augment that line item — no net-new budget required.
- Audit-trail mandate: 21 CFR Part 11, GxP, NABL — LIMS exists because regulators demand provenance. Our provenance-signed graph natively satisfies the same audit requirements, often better.
- Switching cost is the moat: once we are the system of record for sample lineage and experiment state, displacing us means re-validating every protocol. Same dynamic that protects incumbents — flipped to favor us.
- Sample lineage = data lineage: sample tracking is the exact same graph as experimental provenance. We unify two systems that have always been separate.
Integration architecture
Three integration tiers
Tier 1 — Sidecar (Months 0–6): Read-only adapters for STARLIMS, LabWare, LabVantage, Benchling. LabOS reads sample IDs, writes back results + provenance. Customer's existing LIMS stays canonical. Zero validation burden.
Tier 2 — Bidirectional sync (Months 6–18): Two-way integration with conflict resolution. Sample lineage authoritative in LabOS; LIMS gets the human-readable view. Sample management moves into the agent mesh.
Tier 3 — LIMS replacement (Year 2+): For new sites and greenfield CROs, LabOS-native LIMS as a module. Sells as "LabOS Bench" — modern UX, agent-driven, on top of the same graph.
Targeted LIMS / ELN ecosystem
| System | Footprint | Integration priority | Year 1 target |
|---|---|---|---|
| Benchling | Biotech / academic / startup-favored ELN+LIMS | P0 (modern API, ecosystem) | Native two-way sync |
| STARLIMS (Abbott) | Pharma QC, Indian generic pharma | P0 (Sun, Dr Reddy's, Cipla footprint) | Tier-1 sidecar |
| LabWare | Large pharma R&D, Apollo Diagnostics likely | P0 (Apollo integration path) | Tier-1 sidecar |
| LabVantage | Mid-large pharma, biopharma | P1 | Tier-1 sidecar Q4 |
| SampleManager (Thermo) | Analytical labs, Thermo instrument shops | P1 | Q4 connector |
| SapioSciences, Genemod, eLabNext | Modern challengers | P2 | Year 2 if pulled by customer |
The LIMS narrative for pharma BD
"You will not replace your STARLIMS deployment. LabOS sits beside it, gives your scientists agentic experiment design and your QA team better audit trails, and within a year your sample lineage is more searchable than it has ever been. No validation re-cert. No data migration. One signed MSA."
Customer journey
Month 0–3 · Sidecar pilot
Read-only STARLIMS adapter. LabOS reads sample IDs; writes provenance + results back. Zero validation burden.
Month 3–12 · Scientist adoption
Design Agent used for 20%+ of new protocols. Sample lineage searchable across experiments for the first time.
Month 12+ · Expand or replace
Bidirectional sync for greenfield sites, or LabOS Bench module for new labs. Switching cost now favors retention.